Comprehensive Coronary Artery Disease Care in a Safety-Net Hospital: Results of Get With The Guidelines Quality Improvement Initiative

BACKGROUND Adherence to published coronary artery disease (CAD) guidelines is suboptimal, particularly among minorities and the poor. While hospital-based quality-improvement programs may increase the use of evidence-based therapies, little data exist regarding the impact of such programs in sociodemographically disadvantaged (vulnerable) populations. Vulnerable patients in the United States are cared for primarily within the safety-net health system, which comprises urban public hospitals and outpatient community health centers. Denver Health is an example of an integrated system that encompasses both types of facilities. OBJECTIVE To assess evidence-based medication use in CAD patients after initiation of an inpatient quality-improvement program at Denver Health. METHODS We reviewed the medical records of 499 patients with angiographically proven CAD who were hospitalized between July 1998 and December 2002. Patients were prospectively identified through a multidisciplinary intervention led by a nurse manager, and their records were input retrospectively into the American Heart Association's Get With The Guidelines patient management tool. The association's program, which recommends initiating 4 cardioprotective drug classes while patients are hospitalized, was started 2 years into the observation period (August 2000). Treatment rates were compared over the ensuing years. We evaluated temporal trends in discharge use of 4 drugs: (1) betablockers, (2) angiotensin-converting enzyme inhibitors (ACEIs), (3) hydroxymethylglutaryl coenzyme A reductase inhibitors (statins), and (4) aspirin. We calculated the proportion of eligible patients (no documented contraindication) who were prescribed each drug category as well as the proportion who received all 4 drug categories, our principal composite outcome. If any one drug was absent, the composite criterion was considered unmet. RESULTS We observed progressive improvement in discharge use of the 4- drug composite: 18% in 1998-1999 (95% confidence interval [CI], 12%-25%), 50% in 2000 (95% CI, 37%-63%), 62% (95% CI, 54%-70%) in 2001, and 72% (65%-79%) in 2002 (P <0.001 for between-year differences). Among eligible patients discharged in 2002, 90% received beta-blockers, 91% received ACEIs, 86% received statins, and 93% received aspirin. CONCLUSIONS Implementation of a multidisciplinary program led by a nurse manager was associated with increased CAD guideline compliance among sociodemographically disadvantaged patients. This compliance exceeded national averages. Achievement of the composite measure of use of all 4 recommended drug categories at discharge improved from 18% in 1998-1999 to 72% in 2002.

[1]  P. Box Long-term adherence to evidence-based secondary prevention therapies in coronary artery disease , 2006 .

[2]  Robert Parrish,et al.  Guideline-based standardized care is associated with substantially lower mortality in medicare patients with acute myocardial infarction: the American College of Cardiology's Guidelines Applied in Practice (GAP) Projects in Michigan. , 2005, Journal of the American College of Cardiology.

[3]  E. Braunwald,et al.  Early initiation of lipid-lowering therapy for acute coronary syndromes improves compliance with guideline recommendations: observations from the Orbofiban in Patients with Unstable Coronary Syndromes (OPUS-TIMI 16) trial. , 2005, American heart journal.

[4]  Jennifer G. Robinson,et al.  A "poly-portfolio" for secondary prevention: a strategy to reduce subsequent events by up to 97% over five years. , 2005, The American journal of cardiology.

[5]  K. Eagle,et al.  Comparison of outcomes in acute coronary syndrome in patients receiving statins within 24 hours of onset versus at later times. , 2004, The American journal of cardiology.

[6]  C. Long,et al.  Impact of a Cardiac Risk Reduction Program in Vulnerable Patients Hospitalized with Coronary Artery Disease , 2004, Pharmacotherapy.

[7]  R. Gliklich,et al.  Get with the guidelines for cardiovascular secondary prevention: pilot results. , 2004, Archives of internal medicine.

[8]  K. Dickstein,et al.  Effect of combined statin and beta-blocker treatment on one-year morbidity and mortality after acute myocardial infarction associated with heart failure. , 2004, The American journal of cardiology.

[9]  K. Eagle,et al.  Impact of Combination Evidence-Based Medical Therapy on Mortality in Patients With Acute Coronary Syndromes , 2004, Circulation.

[10]  J. LeLorier,et al.  Intensive versus moderate lipid lowering with statins after acute coronary syndromes. , 2004, The New England journal of medicine.

[11]  T. Pearson,et al.  Bridging the treatment gap: improving compliance with lipid-modifying agents and therapeutic lifestyle changes. , 2003, Preventive cardiology.

[12]  P. Gabow,et al.  Denver Health: A Model for the Integration of a Public Hospital and Community Health Centers , 2003, Annals of Internal Medicine.

[13]  S. Jencks,et al.  Change in the quality of care delivered to Medicare beneficiaries, 1998-1999 to 2000-2001. , 2003, JAMA.

[14]  R. Stafford,et al.  The underutilization of cardiac medications of proven benefit, 1990 to 2002. , 2003, Journal of the American College of Cardiology.

[15]  Sankey V. Williams,et al.  ACC/AHA 2002 guideline update for the management of patients with chronic stable angina--summary article: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines (Committee on the Management of Patients With Chronic Stable Angina). , 2003, Journal of the American College of Cardiology.

[16]  R. Califf,et al.  Underuse of aspirin in a referral population with documented coronary artery disease. , 2002, The American journal of cardiology.

[17]  Robert Parrish,et al.  Improving quality of care for acute myocardial infarction: The Guidelines Applied in Practice (GAP) Initiative. , 2002, JAMA.

[18]  M. Mccarthy US heart-guidelines strategy makes promising start , 2001, The Lancet.

[19]  R. Califf,et al.  Effect of lipid-lowering therapy on early mortality after acute coronary syndromes: an observational study , 2001, The Lancet.

[20]  A. Gawlinski,et al.  Improved treatment of coronary heart disease by implementation of a Cardiac Hospitalization Atherosclerosis Management Program (CHAMP). , 2001, The American journal of cardiology.

[21]  D. Wood,et al.  Clinical reality of coronary prevention guidelines: a comparison of EUROASPIRE I and II in nine countries , 2001, The Lancet.

[22]  K. Thygesen,et al.  Erratum: Myocardial infarction redefined - A consensus document of the Joint European Society of Cardiology/American College of Cardiology Committee for the Redefinition of Myocardial Infarction (Journal of the American College of Cardiology (2000) 36 (959-969)) , 2001 .

[23]  B. Horne,et al.  Usefulness of in-hospital prescription of statin agents after angiographic diagnosis of coronary artery disease in improving continued compliance and reduced mortality. , 2001, The American journal of cardiology.

[24]  J. Tu,et al.  Use of the statins in patients after acute myocardial infarction: does evidence change practice? , 2001, Archives of internal medicine.

[25]  William Branch,et al.  Clinical Inertia , 2001, Annals of Internal Medicine.

[26]  J S Alpert,et al.  Myocardial infarction redefined--a consensus document of The Joint European Society of Cardiology/American College of Cardiology Committee for the redefinition of myocardial infarction. , 2000, Journal of the American College of Cardiology.

[27]  S. Yusuf,et al.  Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. , 2000 .

[28]  N. Wenger,et al.  Changes in plasma cholesterol levels after hospitalization for acute coronary events. , 1996, Cardiology.

[29]  S. Shea,et al.  Correlates of nonadherence to hypertension treatment in an inner-city minority population. , 1992, American journal of public health.

[30]  M. Cowan,et al.  American Heart Association. , 2018, P & T : a peer-reviewed journal for formulary management.